Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2).

Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL; PRAISE-2 Study Group.

JACC Heart Fail. 2013 Aug;1(4):308-14. doi: 10.1016/j.jchf.2013.04.004. Epub 2013 Aug 5.

PMID:
24621933
2.

Quantitative analysis of cryo-EM density map segmentation by watershed and scale-space filtering, and fitting of structures by alignment to regions.

Pintilie GD, Zhang J, Goddard TD, Chiu W, Gossard DC.

J Struct Biol. 2010 Jun;170(3):427-38. doi: 10.1016/j.jsb.2010.03.007. Epub 2010 Mar 23.

3.

Identifying Components in 3D Density Maps of Protein Nanomachines by Multi-scale Segmentation.

Pintilie G, Zhang J, Chiu W, Gossard D.

IEEE NIH Life Sci Syst Appl Workshop. 2009 Apr 1;2009:44-47.

4.

Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan.

de Denus S, Zakrzewski-Jakubiak M, Dubé MP, Bélanger F, Lepage S, Leblanc MH, Gossard D, Ducharme A, Racine N, Whittom L, Lavoie J, Touyz RM, Turgeon J, White M.

Ann Pharmacother. 2008 Jul;42(7):925-32. doi: 10.1345/aph.1K657. Epub 2008 Jul 1.

PMID:
18594050
5.

Rhythm control versus rate control for atrial fibrillation and heart failure.

Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators.

N Engl J Med. 2008 Jun 19;358(25):2667-77. doi: 10.1056/NEJMoa0708789.

6.

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.

Michaud V, Vanier MC, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O'Hara G, Gossard D, Champagne M, Goodman K, Renaud Y, Brown A, Phillips M, Ajami AM, Turgeon J.

Clin Pharmacol Ther. 2008 May;83(5):740-8. Epub 2007 Nov 14.

PMID:
18030307
7.

Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.

White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R.

J Card Fail. 2007 Mar;13(2):86-94.

PMID:
17395047
8.

Stalled folding mutants in the triple beta-helix domain of the phage P22 tailspike adhesin.

Weigele PR, Haase-Pettingell C, Campbell PG, Gossard DC, King J.

J Mol Biol. 2005 Dec 16;354(5):1103-17. Epub 2005 Oct 27.

PMID:
16289113
9.

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators.

N Engl J Med. 2003 Nov 13;349(20):1893-906. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.

10.

Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise.

Homsy W, Yan K, Houle JM, Besner JG, Gossard D, Pierce CH, Caillé G.

J Clin Pharmacol. 1997 Aug;37(8):728-36.

PMID:
9378845
11.

Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women.

Keung AC, Landriault H, Lefebvre M, Gossard D, Dempsey EE, Juneau M, Dimmitt D, Castles M, Roberts L, Spenard J.

Biopharm Drug Dispos. 1997 May;18(4):361-9.

PMID:
9158883
12.

The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime.

Thiffault J, Landriault H, Gossard D, Raymond M, Caille G, Spenard J.

Biopharm Drug Dispos. 1996 Mar;17(2):107-15.

PMID:
8907717
13.

Long-term risk stratification with dipyridamole imaging.

Lette J, Bertrand C, Gossard D, Ruscito O, Cerino M, McNamara D, Picard M, Eybalin MC, Levasseur A, Nattel S.

Am Heart J. 1995 May;129(5):880-6.

PMID:
7732976
14.

Pharmacokinetics and pharmacodynamics of a slow-release formulation of diltiazem after the administration of a single and repeated doses to healthy volunteers.

Lefebvre M, Lacasse Y, Spénard J, Geadah D, Moisan R, Gossard D, Landriault H, Du Souich P, Caillé G.

Biopharm Drug Dispos. 1994 Apr;15(3):227-42.

PMID:
7880983
15.

Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers.

Guimont S, Landriault H, Klischer K, Grace M, Lambert C, Caillé G, Gossard D, Russell A, Raymond M, Hutchings E, et al.

Biopharm Drug Dispos. 1993 Dec;14(9):767-78.

PMID:
8298070
16.

Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans.

Qureshi S, Laganière S, Caillé G, Gossard D, Lacasse Y, McGilveray I.

Pharm Res. 1992 May;9(5):683-6.

PMID:
1608903
17.

Transplantation and lipids.

Gossard D, Langlais J.

CMAJ. 1991 Apr 15;144(8):1003. No abstract available.

18.

Les nitrates: thérapie utile malgré le phénomène de tolérance.

Gossard D, Tardif JC.

Can Fam Physician. 1991 Mar;37:657-660. French.

19.

Limited usefulness of intermittent nitroglycerin patches in stable angina.

Waters DD, Juneau M, Gossard D, Choquette G, Brien M.

J Am Coll Cardiol. 1989 Feb;13(2):421-5.

20.

Early return to work after uncomplicated myocardial infarction. Results of a randomized trial.

Dennis C, Houston-Miller N, Schwartz RG, Ahn DK, Kraemer HC, Gossard D, Juneau M, Taylor CB, DeBusk RF.

JAMA. 1988 Jul 8;260(2):214-20.

PMID:
3385897
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk